Team

IPI_AUG18_738.jpg

The IPI was designed in consultation with experts from the academic, biotechnology, pharmaceutical, and venture capital communities. The IPI is helmed by a Board of Directors representing all major stakeholder groups. The IPI has enlisted a world-class team of scientists as members of the Scientific Advisory Board, which will offer scientific guidance and oversight to ensure IPI resources are devoted to the most pressing challenges in protein research.

 

Leadership

IMG_0524.jpg
Co-Founder and Executive Chair    Timothy A. Springer, Ph.D.  is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Co-Founder and Executive Chair

Timothy A. Springer, Ph.D. is the Latham Family Professor at Harvard Medical School and Boston Children’s Hospital. He is a world leader in structural biology and immunology. He is also a founder and private investor in biopharmaceutical ventures including LeukoSite, Scholar Rock, Morphic Therapeutic, Moderna Therapeutic, Editas Medicine, Selecta Biosciences, and Ab Initio Biotherapeutics. His research and company formation has led to six FDA-approved drugs, including antibodies for treating cancer and immune diseases.

Co-Founder    Andrew Kruse, Ph.D.  is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.

Co-Founder

Andrew Kruse, Ph.D. is Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School. His lab studies the molecular basis of membrane protein signaling important in human health and disease using biophysical techniques and structural biology. Andrew was selected for the 2016 Forbes “30 under 30” list, and is the recipient of notable awards including an NIH Director’s Early Independence Award and a Sloan Research Fellowship. He is a founder of Ab Initio Biotherapeutics.

Chief Innovation Officer    Steven C. Almo, Ph.D. , is Professor and Chair of the Department of Biochemistry and Professor of Physiology & Biophysics at Albert Einstein College of Medicine. He is an internationally recognized leader in the field of structural biology and immunology. His lab has been at the center of advancing high-throughput methods for expressing proteins, determining their structure, and interrogating their function, as well as developing innovative receptor-ligand de-orphaning platforms. Dr. Almo is also a Co-Founder and Chair of the Scientific Advisory Board of Cue Biopharma.

Chief Innovation Officer

Steven C. Almo, Ph.D., is Professor and Chair of the Department of Biochemistry and Professor of Physiology & Biophysics at Albert Einstein College of Medicine. He is an internationally recognized leader in the field of structural biology and immunology. His lab has been at the center of advancing high-throughput methods for expressing proteins, determining their structure, and interrogating their function, as well as developing innovative receptor-ligand de-orphaning platforms. Dr. Almo is also a Co-Founder and Chair of the Scientific Advisory Board of Cue Biopharma.

 
 
Acting Chief Operations Officer; Director of Target Discovery    Wei Yang, Ph.D.  was Director of the Molecular Biology Department at Novo Nordisk Research Centre China, and also Project Manager in Global Research at Novo Nordisk. He led an international team that successfully produced and screened for interactions between all human secreted proteins and single transmembrane cell surface proteins. This receptor-ligand de-orphaning effort identified the previously unknown receptors for GDF15 and VISTA, which are novel therapeutic targets for obesity and cancer, respectively.

Acting Chief Operations Officer; Director of Target Discovery

Wei Yang, Ph.D. was Director of the Molecular Biology Department at Novo Nordisk Research Centre China, and also Project Manager in Global Research at Novo Nordisk. He led an international team that successfully produced and screened for interactions between all human secreted proteins and single transmembrane cell surface proteins. This receptor-ligand de-orphaning effort identified the previously unknown receptors for GDF15 and VISTA, which are novel therapeutic targets for obesity and cancer, respectively.

Director of Philanthropy    Sharon Klein  previously led philanthropy and development initiatives for the Massachusetts and Rhode Island chapters of the Leukemia and Lymphoma Society, where she served first as the Director of Development and then later as Executive Director. In these roles, Ms. Klein managed operations of both chapters, oversaw successful fundraising campaigns focused on large gifts, and promoted growth in corporate sponsorship, donor development, and mission initiatives.

Director of Philanthropy

Sharon Klein previously led philanthropy and development initiatives for the Massachusetts and Rhode Island chapters of the Leukemia and Lymphoma Society, where she served first as the Director of Development and then later as Executive Director. In these roles, Ms. Klein managed operations of both chapters, oversaw successful fundraising campaigns focused on large gifts, and promoted growth in corporate sponsorship, donor development, and mission initiatives.

Head of Antibody Discovery    Joseph Jardine, Ph.D.  trained at the University of Washington under William Schief, Ph.D. and David Baker, Ph.D., focusing on rational protein design and engineering. In 2011, he moved with the Schief lab to The Scripps Research Institute where he developed germline-targeting immunogens and designed immunization strategies to elicit broadly neutralizing antibodies against HIV. Dr. Jardine received postdoctoral training under Dennis Burton, Ph.D. at Scripps where he continued his work on HIV vaccine development.

Head of Antibody Discovery

Joseph Jardine, Ph.D. trained at the University of Washington under William Schief, Ph.D. and David Baker, Ph.D., focusing on rational protein design and engineering. In 2011, he moved with the Schief lab to The Scripps Research Institute where he developed germline-targeting immunogens and designed immunization strategies to elicit broadly neutralizing antibodies against HIV. Dr. Jardine received postdoctoral training under Dennis Burton, Ph.D. at Scripps where he continued his work on HIV vaccine development.

 
 
Head of Protein Design    Christopher D. Bahl, Ph.D.  studied the molecular mechanisms of bacterial host-pathogen interaction as a graduate student with Dean R. Madden, Ph.D. at the Geisel School of Medicine at Dartmouth. During his postdoctoral studies with David Baker, Ph.D. at the University of Washington, Chris developed computational design methods and laboratory tools to create hyperstable, constrained peptides  de novo ; these molecules represent a family of biologic drug scaffolds with enormous potential.   Bahl Lab

Head of Protein Design

Christopher D. Bahl, Ph.D. studied the molecular mechanisms of bacterial host-pathogen interaction as a graduate student with Dean R. Madden, Ph.D. at the Geisel School of Medicine at Dartmouth. During his postdoctoral studies with David Baker, Ph.D. at the University of Washington, Chris developed computational design methods and laboratory tools to create hyperstable, constrained peptides de novo; these molecules represent a family of biologic drug scaffolds with enormous potential.

Bahl Lab

Financial Controller    Annette Randazza  is a strong business finance professional with experience in the Life Sciences arena. Prior to joining IPI, Annette was employed at Cell Signaling Technology (CST) for 15 years where she served as Financial Controller, Director of Operations, and Director of Procurement. Annette managed multiple aspects of CST's expanding business including grants, royalties, small business loans, procurement, vendor negotiations, and logistics agreements. Annette’s knowledge of business and life science make her an integral addition to the IPI team.

Financial Controller

Annette Randazza is a strong business finance professional with experience in the Life Sciences arena. Prior to joining IPI, Annette was employed at Cell Signaling Technology (CST) for 15 years where she served as Financial Controller, Director of Operations, and Director of Procurement. Annette managed multiple aspects of CST's expanding business including grants, royalties, small business loans, procurement, vendor negotiations, and logistics agreements. Annette’s knowledge of business and life science make her an integral addition to the IPI team.

 
 
 

Board of Directors

IMG_9210.jpg
Board of Directors    Jeffrey Flier, M.D.  is the Higginson Professor of Physiology and Medicine at Harvard Medical School and a leading authority in the molecular causes of obesity and diabetes. Dr. Flier served as the 21st Dean of the Faculty of Medicine at Harvard University, and he serves on the boards of several nonprofits including Brandeis University and companies including Scholar Rock.

Board of Directors

Jeffrey Flier, M.D. is the Higginson Professor of Physiology and Medicine at Harvard Medical School and a leading authority in the molecular causes of obesity and diabetes. Dr. Flier served as the 21st Dean of the Faculty of Medicine at Harvard University, and he serves on the boards of several nonprofits including Brandeis University and companies including Scholar Rock.

Board of Directors    Maykin Ho, Ph.D.  retired as Partner of Goldman Sachs & Co. after 24 years, which included serving as Advisory Director of Global Healthcare Investment Banking and co-head of US Healthcare for Global Investment Research. She is a venture partner of Qiming Venture Partners and serves on the board of directors for Agios Pharmaceuticals, Parexel International, and the Aaron Diamond AIDS Research Center.

Board of Directors

Maykin Ho, Ph.D. retired as Partner of Goldman Sachs & Co. after 24 years, which included serving as Advisory Director of Global Healthcare Investment Banking and co-head of US Healthcare for Global Investment Research. She is a venture partner of Qiming Venture Partners and serves on the board of directors for Agios Pharmaceuticals, Parexel International, and the Aaron Diamond AIDS Research Center.

Board of Directors    Amir Nashat, Ph.D.  is a Managing Partner at Polaris Partners and focuses on investments in healthcare. He currently represents Polaris as a Director of eight biotechnology startup companies and has served as a Director of seven others. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

Board of Directors

Amir Nashat, Ph.D. is a Managing Partner at Polaris Partners and focuses on investments in healthcare. He currently represents Polaris as a Director of eight biotechnology startup companies and has served as a Director of seven others. He has been named to the Forbes Midas List of “Top 100 Venture Capitalists.”

 
 
Board of Directors    Normand F. Smith  is an attorney and partner at the firm Burns & Levinson, LLC. Normand has extensive experience in the areas of intellectual property, tax planning, and the formation and management of businesses in biotech. He has advised biotech entrepreneurs and scientists and served as general counsel to biotech companies. 

Board of Directors

Normand F. Smith is an attorney and partner at the firm Burns & Levinson, LLC. Normand has extensive experience in the areas of intellectual property, tax planning, and the formation and management of businesses in biotech. He has advised biotech entrepreneurs and scientists and served as general counsel to biotech companies. 

Board of Directors, Scientific Advisory Board    K. Dane Wittrup, Ph.D.  is the Carbon P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT, and is the Associate Director of the Koch Institute for Integrative Cancer Research. Dr. Wittrup is responsible for most of the recent advances in directed evolution of biopharmaceutical proteins, including antibodies. He is a co-founder and CSO of Adimab and a co-founder and Scientific Advisory Board member of Eleven Biotherapeutics.

Board of Directors, Scientific Advisory Board

K. Dane Wittrup, Ph.D. is the Carbon P. Dubbs Professor of Chemical Engineering and Biological Engineering at MIT, and is the Associate Director of the Koch Institute for Integrative Cancer Research. Dr. Wittrup is responsible for most of the recent advances in directed evolution of biopharmaceutical proteins, including antibodies. He is a co-founder and CSO of Adimab and a co-founder and Scientific Advisory Board member of Eleven Biotherapeutics.

 

Scientific Advisory Board

1U6A9035.jpg
David Baker, Ph.D.   Professor of Biochemistry at University of Washington and Investigator of Howard Hughes Medical Institute.

David Baker, Ph.D.

Professor of Biochemistry at University of Washington and Investigator of Howard Hughes Medical Institute.

Stephen Blacklow, M.D., Ph.D   Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Stephen Blacklow, M.D., Ph.D

Gustavus Adolphus Pfeiffer Professor and Chair of the Department of Biological Chemistry and Molecular Pharmacology at Harvard Medical School.

Shuqi Chen, Ph.D.   Founder, former CEO, and former Chairman of the Board of IQuum, Inc. and Former Vice President, Research and Development of Point of Care at Roche Molecular System.

Shuqi Chen, Ph.D.

Founder, former CEO, and former Chairman of the Board of IQuum, Inc. and Former Vice President, Research and Development of Point of Care at Roche Molecular System.

 
 
George Church, Ph.D.   Founding Faculty & Synthetic Biology Lead at the Wyss Institute, Robert Winthrop Professor of Genetics at Harvard Medical School, and Professor of Health Sciences & Technology at Harvard and MIT.

George Church, Ph.D.

Founding Faculty & Synthetic Biology Lead at the Wyss Institute, Robert Winthrop Professor of Genetics at Harvard Medical School, and Professor of Health Sciences & Technology at Harvard and MIT.

Richard Cummings, Ph.D.   Director of the National Center for Functional Glycomics and Professor of Surgery at Beth Israel Deaconess Medical Center & Harvard Medical School.

Richard Cummings, Ph.D.

Director of the National Center for Functional Glycomics and Professor of Surgery at Beth Israel Deaconess Medical Center & Harvard Medical School.

Eric Fischer, Ph.D.   Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute

Eric Fischer, Ph.D.

Assistant Professor of Biological Chemistry and Molecular Pharmacology at Harvard Medical School and Principal Investigator in the Department of Cancer Biology at Dana-Farber Cancer Institute

 
 
K. Christopher Garcia, Ph.D.   Professor of Molecular and Cellular Physiology and of Structural Biology at Stanford University School of Medicine and Investigator at the Howard Hughes Medical Institute.

K. Christopher Garcia, Ph.D.

Professor of Molecular and Cellular Physiology and of Structural Biology at Stanford University School of Medicine and Investigator at the Howard Hughes Medical Institute.

Michael Gladstone   Principal at Atlas Venture.

Michael Gladstone

Principal at Atlas Venture.

Stephen Harrison, Ph.D.   Giovanni Armenise-Harvard Professor of Basic Medical Sciences, Harvard Medical School and Boston Children's Hospital, and Investigator in the Howard Hughes Medical Institute.

Stephen Harrison, Ph.D.

Giovanni Armenise-Harvard Professor of Basic Medical Sciences, Harvard Medical School and Boston Children's Hospital, and Investigator in the Howard Hughes Medical Institute.

 
 
John Hastewell, D. Phil.   Former Head of the Novartis Institutes for BioMedical Research Biologics Center (NBC)

John Hastewell, D. Phil.

Former Head of the Novartis Institutes for BioMedical Research Biologics Center (NBC)

Brian Kobilka, M.D.   Professor of Molecular and Cellular Physiology, and Hélène Irwin Fagan Chair in Cardiology at Stanford University School of Medicine.

Brian Kobilka, M.D.

Professor of Molecular and Cellular Physiology, and Hélène Irwin Fagan Chair in Cardiology at Stanford University School of Medicine.

Nilesh Kumar, M.B.A., Ph.D.   Partner at Novo Ventures (US), Inc.

Nilesh Kumar, M.B.A., Ph.D.

Partner at Novo Ventures (US), Inc.

 
 
Judy Lieberman, M.D., Ph.D.   Chair of the Program in Cellular and Molecular Medicine at Boston Children's Hospital and Professor of Pediatrics at Harvard Medical School.

Judy Lieberman, M.D., Ph.D.

Chair of the Program in Cellular and Molecular Medicine at Boston Children's Hospital and Professor of Pediatrics at Harvard Medical School.

Harvey F. Lodish, Ph.D.   Professor of Biology and of Biological Engineering at MIT and founding member of the Whitehead Institute for Biomedical Research. Co-founder of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals, and Rubius

Harvey F. Lodish, Ph.D.

Professor of Biology and of Biological Engineering at MIT and founding member of the Whitehead Institute for Biomedical Research. Co-founder of Genzyme, Arris Pharmaceuticals, Millennium Pharmaceuticals, and Rubius

Deborah Marks, Ph.D.   Associate Professor of Systems Biology and Director of the Raymond and Beverly Sackler Laboratory at Harvard Medical School.

Deborah Marks, Ph.D.

Associate Professor of Systems Biology and Director of the Raymond and Beverly Sackler Laboratory at Harvard Medical School.

 
 
Werner Meier   Principal at Werner Meier Biologics LLC.

Werner Meier

Principal at Werner Meier Biologics LLC.

Timothy Mitchison, Ph.D.   Hasib Sabbagh Professor of Systems Biology at Harvard Medical School.

Timothy Mitchison, Ph.D.

Hasib Sabbagh Professor of Systems Biology at Harvard Medical School.

Saurabh Saha, M.D., Ph.D.   Senior Vice President R&D and Global Head of Translational Medicine at Bristol-Myers Squibb

Saurabh Saha, M.D., Ph.D.

Senior Vice President R&D and Global Head of Translational Medicine at Bristol-Myers Squibb

 
 
Arlene Sharpe, M.D., Ph.D.   George Fabyan Professor of Comparative Pathology and Interim Co-Chair, Microbiology and Immunobiology at Harvard Medical School. Co-Director, Evergrande Center for Immunologic Diseases at Brigham and Women's Hospital and Harvard Medical School.

Arlene Sharpe, M.D., Ph.D.

George Fabyan Professor of Comparative Pathology and Interim Co-Chair, Microbiology and Immunobiology at Harvard Medical School.
Co-Director, Evergrande Center for Immunologic Diseases at Brigham and Women's Hospital and Harvard Medical School.

Will Somers, Ph.D.   Vice President of Global Biotherapeutic Technologies at Pfizer.

Will Somers, Ph.D.

Vice President of Global Biotherapeutic Technologies at Pfizer.

Ulrich von Andrian, M.D., Ph.D.   Mallinckrodt Professor of Immunopathology at Harvard Medical School.

Ulrich von Andrian, M.D., Ph.D.

Mallinckrodt Professor of Immunopathology at Harvard Medical School.

 
 
Christopher Walsh, M.D., Ph.D.   Chief, Division of Genetics at Boston Childrens Hospital, Bullard Professor of Pediatrics and Neurology at Harvard Medical School

Christopher Walsh, M.D., Ph.D.

Chief, Division of Genetics at Boston Childrens Hospital, Bullard Professor of Pediatrics and Neurology at Harvard Medical School

Leonard I. Zon, M.D.   Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, Director of the Stem Cell Program, Children’s Hospital Boston, and Co-founder of Scholar Rock.

Leonard I. Zon, M.D.

Grousbeck Professor of Pediatric Medicine at Harvard Medical School, Investigator at Howard Hughes Medical Institute, Director of the Stem Cell Program, Children’s Hospital Boston, and Co-founder of Scholar Rock.

 

Careers

IPI_AUG18_624.jpg

Current Openings: